Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
PSK Pharma launches the second anti-HIV drug in a year
- By Newsdesk
- Russia
- Jun 08, 2023
PSK Pharma, a pharmaceutical company, has received a registration certificate for a medicinal product (MP) based on raltegravir (included in the list of Vital and Essential Drugs). According to the website of the Moscow region's government, the drug, whose production is located on the territory of the Dubna SEZ near Moscow, is intended for the treatment of HIV-1 infection in patients as young as six, in combination with other antiretroviral drugs.
"By launching the production of this drug, PSK Pharma makes a significant contribution to the import substitution of the most important drugs," the regional Ministry of Investment stated, adding that two other companies (Pharmasintez and Promomed) are also involved in the production of raltegravir-based medicines in Russia. The department's press service also clarified that the patent for the original raltegravir molecule would expire in the autumn of 2022.
Raltegravir is PSK Pharma's second HIV drug to be introduced to the Russian market since the beginning of 2023. Previously, the antiretroviral drug "Ritonavir" was granted registration. Furthermore, the company's product portfolio includes two additional anti-HIV drugs: oral Fosamprenavir and Etravirine, both of which can be used as early as the age of two.
MSD (Netherlands) charges around 20,000 rubles for raltegravir, while Russian "Pharmasintez" and "Promomed" charge 13,000 and 15,000 rubles, respectively.